Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

423
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
423
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

2.3K
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
2.3K
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

414
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
414
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

2.3K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.3K
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

5.4K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
5.4K
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

305
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
305

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase I/II trial of concurrent chemo-hormonal enzalutamide and cabazitaxel in patients with metastatic castration-resistant prostate cancer.

The oncologist·2026
Same author

Androgen deprivation therapy and kidney function in patients with prostate cancer: an analysis of the RADICAL-PC cohort.

International urology and nephrology·2026
Same author

Comparing virtual and in-person training for intracavernosal injection therapy in a multidisciplinary sexual health clinic within a prostate cancer survivorship program.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada·2025
Same author

Reply by Authors.

The Journal of urology·2025
Same author

A Tailored Electronic Survivorship Care Plan for Prostate Cancer Survivors: A Multicenter Randomized Controlled Trial.

The Journal of urology·2024
Same author

The Discrepancy Between Patient-reported Outcomes, Adverse Events, and Radiographic Progression-free Survival in MAGNITUDE and Other Recent Trials.

European urology·2024

Related Experiment Video

Updated: Apr 30, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.4K

Intermittent versus continuous androgen deprivation therapy.

Celestia S Higano1

  • 1From the University of Washington, Seattle Cancer Care Alliance, Seattle, Washington.

Journal of the National Comprehensive Cancer Network : JNCCN
|May 10, 2014
PubMed
Summary

Intermittent androgen deprivation therapy (ADT) is not inferior to continuous ADT for overall survival in men with rising PSA after treatment. Quality of life may improve with intermittent ADT, especially for those with side effects.

More Related Videos

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

6.8K
Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

46.8K

Related Experiment Videos

Last Updated: Apr 30, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.4K
Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

6.8K
Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

46.8K

Area of Science:

  • Oncology
  • Urology
  • Clinical Trials

Background:

  • Androgen deprivation therapy (ADT) is a cornerstone for metastatic prostate cancer.
  • Continuous versus intermittent ADT administration remains a subject of clinical debate.

Purpose of the Study:

  • To compare overall survival and quality of life between continuous and intermittent ADT administration in two large phase III trials.
  • To evaluate the noninferiority of intermittent ADT compared to continuous ADT.

Main Methods:

  • Two large phase III trials (NCIC PR-7 and SWOG 9346) compared continuous and intermittent ADT.
  • NCIC PR-7: Men with rising PSA post-definitive therapy. SWOG 9346: Men with newly diagnosed metastatic disease.
  • Primary endpoint: Overall survival using a noninferiority design.

Main Results:

  • NCIC trial: Intermittent ADT was not inferior to continuous ADT for overall survival.
  • SWOG trial: Noninferiority of intermittent ADT for survival was inconclusive.
  • Both trials reported improved quality of life in certain domains with intermittent ADT.

Conclusions:

  • Intermittent ADT is a viable option for men with biochemical relapse and rising PSA, particularly if side effects are a concern, except for those with Gleason score ≥8.
  • Continuous ADT remains the standard for metastatic disease due to inconclusive noninferiority data from SWOG 9346.
  • Risk stratification (PSA level, pain) may guide intermittent vs. continuous ADT choice in metastatic prostate cancer patients experiencing side effects.